Pre-licensure clinical trials demonstrated that both aP5gen and TdaP5gen are safe, and are more immunogenic and induce persisting higher antibody responses against pertussis toxin (PT) and FHA than chemically inactivated pertussis booster vaccines (Tdapchem) [13], [14], [15]. The gene discussed is F2; the disease is pertussis.